ArticleBMC infectious diseases2013
The discovery and identification of a candidate proteomic biomarker of active tuberculosis.
Article in BMC infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- Elucidation of a Human Urine Metabolite as a Seryl-Leucine Glycopeptide and as a Biomarker of Effective Anti-Tuberculosis Therapy.ACS infectious diseases · 2019Trial
- Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis.Tuberculosis (Edinburgh, Scotland) · 2018Trial
- Diagnostic value and prognostic effect of has-miR-151a-3p in tuberculosis.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2026Article
- Candidate serum protein biomarkers for active pulmonary tuberculosis diagnosis in tuberculosis endemic settings.BMC infectious diseases · 2024Article
- Integrated plasma proteomics identifies tuberculosis-specific diagnostic biomarkers.JCI insight · 2024Article
- Article
- Diagnostic biomarkers for active tuberculosis: progress and challenges.EMBO molecular medicine · 2022Review
- High miRNA-378 expression has high diagnostic values for pulmonary tuberculosis and predicts adverse outcomes.BMC molecular and cell biology · 2022Article
- Proteomics in Biomarker Discovery for Tuberculosis: Current Status and Future Perspectives.Frontiers in microbiology · 2022Review
- Rapid Discrimination and Authentication of Korean Farmstead Mozzarella Cheese through MALDI-TOF and Multivariate Statistical Analysis.Metabolites · 2021Article
- Evaluation of Host Serum Protein Biomarkers of Tuberculosis in sub-Saharan Africa.Frontiers in immunology · 2021Article
- Serum sCD14, PGLYRP2 and FGA as potential biomarkers for multidrug-resistant tuberculosis based on data-independent acquisition and targeted proteomics.Journal of cellular and molecular medicine · 2020Article
- Elevated pulmonary tuberculosis biomarker miR-423-5p plays critical role in the occurrence of active TB by inhibiting autophagosome-lysosome fusion.Emerging microbes & infections · 2019Article
- "Tuberculosis in advanced HIV infection is associated with increased expression of IFNγ and its downstream targets".BMC infectious diseases · 2018Article
- Potential Immunological Biomarkers for Detection of Mycobacterium tuberculosis Infection in a Setting Where M. tuberculosis Is Endemic, Ethiopia.Infection and immunity · 2018Article
- Identification of a Novel Serum Biomarker for Tuberculosis Infection in Chinese HIV Patients by iTRAQ-Based Quantitative Proteomics.Frontiers in microbiology · 2018Article
- Label-Free Quantitative Proteomics Identifies Novel Plasma Biomarkers for Distinguishing Pulmonary Tuberculosis and Latent Infection.Frontiers in microbiology · 2018Article
- Characterization of plasma proteins in children of differentOncotarget · 2017Article
- Serum amyloid A, protein Z, and C4b-binding protein β chain as new potential biomarkers for pulmonary tuberculosis.PloS one · 2017Article
- Diagnostic 'omics' for active tuberculosis.BMC medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNoninvasive and convenient biomarkers for early diagnosis of tuberculosis (TB) remain an urgent need. The aim of this study was to discover and identify potential biomarkers specific for TB.
methodsThe surface-enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF MS) combined with weak cation exchange (WCX) magnetic beads was used to screen serum samples from 180 cases of TB and 211 control subjects. A classification model was established by Biomarker Pattern Software (BPS). Candidate protein biomarkers were purified by reverse phase-high performance liquid chromatography (RP-HPLC), identified by MALDI-TOF MS, LC-MS/MS and validated using enzyme-linked immunosorbent assay (ELISA).
resultsA total of 35 discriminating m/z peaks were detected that were related to TB (P < 0.01). The model of biomarkers based on the four biomarkers (2554.6, 4824.4, 5325.7, and 8606.8 Da) was established which could distinguish TB from controls with the sensitivity of 83.3% and the specificity of 84.2%. The candidate biomarker with m/z of 2554.6 Da was found to be up-regulated in TB patients, and was identified as a fragment of fibrinogen, alpha polypeptide isoform alpha-E preproprotein. Analysis in 22 patients with TB showed increased fibrinogen degradation product (FDP) (5,005 ± 1,297 vs. 4,010 ± 1,181 ng/mL, P < 0.05) and in 142 patients showed elevated plasma fibrinogen levels.
conclusionsA diagnostic model for TB with high sensitivity and specificity was developed using mass spectrometry combined with magnetic beads. Fibrinogen was identified as a potential biomarker for TB and showed diagnostic values in clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.